• Explore /
  • Poster
  • / A phase II study of perioperative mFOLFOX plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ) and stomach.

A phase II study of perioperative mFOLFOX plus pembrolizumab combination in patients with potentially resectable adenocarcinoma of the esophageal, gastroesophageal junction (GEJ) and stomach.

Abstract Poster

Authors

null

Weijing Sun

University of Kansas Medical Center, Kansas City, KS

Weijing Sun , Anwaar Saeed , Raed Moh'd Taiseer Al-Rajabi , Anup Kasi , Nirmal K Veeramachaneni , Mazin Francis Al-Kasspooles , Joaquina Celebre Baranda , Milind A. Phadnis , Andrew K. Godwin , Mojtaba Olyaee , Rashna Madan , Natalie Streeter , Alykhan Nagji , Stephen K. Williamson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT03488667

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4047)

DOI

10.1200/JCO.2022.40.16_suppl.4047

Abstract #

4047

Poster Bd #

35

Abstract Disclosures

Similar Posters

First Author: Weijing Sun

First Author: Ralf Hofheinz

First Author: Manish A. Shah

First Author: Salah-Eddin Al-Batran